BGM0504 vs RAY1225
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline
BGM0504
Developed by BrightGene Bio-Medical Technology and partners
NCT06973681 · Phase 2 · completed
This randomized, double-blind, placebo-controlled Phase 2 trial enrolled 120 adults with overweight or obesity across three weekly BGM0504 doses and placebo. The primary endpoint was percentage change in body weight from baseline to week 24. A company announcement reported placebo-adjusted mean weight reductions of 10.77% to 19.78% across the BGM0504 dose groups, meeting the primary endpoint. No power calculation or planned enrolment was available to show the trial was adequately powered, and the result is not posted on ClinicalTrials.gov.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: February 2027 · NCT07658560 (registry estimate)
Reported efficacy
Percentage change in body weight (Week 0 to Week 24): Placebo-adjusted LS-mean body weight reductions of 10.77% to 19.78% across BGM0504 dose groups (120 Chinese adults with obesity) (met)
Result source: NCT06973681
RAY1225
Developed by Guangdong Raynovent Biotech and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | BGM0504 | RAY1225 |
|---|---|---|
| Body weight, % change | —Not posted · NCT06704581 | —Trial running · NCT06893016 |
| Weight loss of 5% or more | —Not posted · NCT06704581 | —Trial running · NCT06893016 |
| Weight loss of 10% or more | —Not posted · NCT06704581 | —Trial running · NCT06893016 |
| Waist circumference, change (cm) | —Not posted · NCT06704581 | —Trial running · NCT06893016 |
Body weight, % change
- BGM0504
- —Not posted · NCT06704581
- RAY1225
- —Trial running · NCT06893016
Weight loss of 5% or more
- BGM0504
- —Not posted · NCT06704581
- RAY1225
- —Trial running · NCT06893016
Weight loss of 10% or more
- BGM0504
- —Not posted · NCT06704581
- RAY1225
- —Trial running · NCT06893016
Waist circumference, change (cm)
- BGM0504
- —Not posted · NCT06704581
- RAY1225
- —Trial running · NCT06893016
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
RAY1225: no structured comparison results are available for Obesity.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BGM0504's landscape · RAY1225's landscape